Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 1 art units • 1 examiners • 0 of 2 (0%) have an AI response strategy ready
Quetzal Therapeutics LLC has 1 pending office action in the Biotechnology & Pharmaceuticals sector. This action is being handled by examiner PALENIK, JEFFREY T, who is the only examiner currently assigned to the company's active matters. The portfolio's activity is limited to 1 distinct art unit.
With only 1 pending office action, the current prosecution workload is minimal and centralized. Understanding the specific requirements of this single art unit is essential for advancing the pending application.
Based on the USPTO statutory response window for each pending office action. 2 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (50%) |
| Multi-statute (no §101) | 1 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PALENIK, JEFFREY T | 2 | 53.5% | +27.0% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19349368 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | PALENIK, JEFFREY T | 5d |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 19349368 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | PALENIK, JEFFREY T | 5d |
| 18408664 | High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In Patients | PALENIK, JEFFREY T | 48d |
| Art Unit | Apps |
|---|---|
| 1615 | 2 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 19349368 | HIGH SURFACE-AREA LYOPHILIZED COMPOSITIONS COMPRISING ARSENIC FOR ORAL ADMINISTRATION IN PATIENTS | PALENIK, JEFFREY T | 1615 | §102§103 | Non-Final OA | 5d | Pending | Oct 03, 2025 |
| 18408664 | High Surface-Area Lyophilized Compositions Comprising Arsenic For Oral Administration In Patients | PALENIK, JEFFREY T | 1615 | §103Other | Final Rejection | 48d | Pending | Jan 10, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialQuetzal Therapeutics LLC has 2 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Jeffrey T Palenik has the most, with 2 of Quetzal Therapeutics LLC's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
